

Kentucky Department for Medicaid Services

Pharmacy and Therapeutics Advisory Committee Recommendations

November 15, 2012 Meeting

The following chart provides a summary of the recommendations that were made by the Pharmacy and Therapeutics Advisory Committee at the November 15, 2012 meeting. Review of the recommendations by the Commissioner of the Cabinet for Health and Family Services and final decisions are pending.

	Description of Recommendation	P & T Vote
1	<u>New Products to Market: Dymista[®]</u> Place this product non preferred with similar quantity limits in the PDL class titled Intranasal Rhinitis Agents.	Passed 11 For 0 Against
2	<u>New Products to Market: Sklice[™]</u> Place this product non preferred in the PDL class titled Dermatologics: Antiparasitics, Topical.	Passed 11 For 0 Against
3	<u>New Products to Market: Neupro[®]</u> Place this product non preferred in the PDL class titled Non-Ergot Dopamine Receptor Agonists.	Passed 11 For 0 Against
4	<u>New Products to Market: Viokace[™]</u> Place this product non preferred in the PDL class titled Pancreatic Enzymes.	Passed 11 For 0 Against
5	<u>New Products to Market: Pertzve[™]</u> Place this product non preferred in the PDL class titled Pancreatic Enzymes.	Passed 11 For 0 Against
6	<u>New Products to Market: Myrbetriq[™]</u> Place this product preferred with similar quantity limits in the PDL class titled Urinary Tract Antispasmodics.	Passed 7 For 3 Against 1 Abstention
7	<u>New Products to Market: Tudorza[™] Pressair[™]</u> Place this product non preferred with similar quantity limits in the PDL class titled COPD Agents.	Passed 11 For 0 Against
8	<u>New Products to Market: Xtandi[®]</u> Place this product non preferred with similar quantity limits in the PDL class titled Oral Oncology Agents.	Passed 11 For 0 Against
9	<u>New Products to Market: Bosulif[®]</u> Place this product non preferred with similar quantity limits in the PDL class titled Oral Oncology Agents.	Passed 11 For 0 Against

	Description of Recommendation	P & T Vote
10	<p><u>Truvada[®] Clinical Criteria</u> Truvada[®] should be approved initially if any ONE of the following is true:</p> <ul style="list-style-type: none"> • Treatment of HIV-1 infection; OR • Pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 if ALL of the following are true: <ul style="list-style-type: none"> ○ Prior Authorization request is coming from the prescriber; AND ○ High risk for contracting HIV-1, defined as: <ul style="list-style-type: none"> ▪ Male who has sex with men (MSM) and are at high risk for HIV-1 infection. ▪ Transgender woman, (e.g. male who has undergone a sex change), who has sex with men and are at high risk for HIV-1 infection. ▪ Male or female in a heterosexual HIV-1 serodiscordant relationship; AND ○ Negative HIV-1 test immediately prior to initiating Truvada[®]; AND ○ Risk-reduction and medication adherence counseling has been completed by prescriber. <p>**If the indication is pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1, Truvada[®] will only be approved for a duration of 3 months.</p> <p>Truvada[®] should be approved for continuation of therapy if any ONE of the following is true:</p> <ul style="list-style-type: none"> • Treatment of HIV-1 infection; OR • Pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 if ALL of the following are true: <ul style="list-style-type: none"> ○ Prior Authorization request is coming from the prescriber; AND ○ Substantial, ongoing, high risk for acquiring HIV infection as defined below: <ul style="list-style-type: none"> ▪ Male who has sex with men (MSM) and are at high risk for HIV-1 infection. ▪ Transgender woman, (e.g. male who has undergone a sex change), who has sex with men and are at high risk for HIV-1 infection. ▪ Male or female in a heterosexual HIV-1 serodiscordant relationship; AND ○ Negative HIV-1 test; AND ○ Risk-reduction and medication adherence counseling has been completed by prescriber no less frequently than every three months; AND ○ The patient has strictly adhered to the dosing schedule, as evident by pill counts. 	<p>Passed 7 For 2 Against 2 Abstention</p>

	**If the indication is pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1, Truvada [®] will only be approved for a duration of 3 months.	
11	<p><u>Nucynta[®] ER Clinical Criteria</u></p> <p>Nucynta[®] ER should be authorized for the following diagnoses:</p> <ul style="list-style-type: none"> • Pain after trial and failure of one preferred product; OR • Diabetic Peripheral Neuropathy after trial and failure of TWO of the following: <ul style="list-style-type: none"> ○ One SNRI; or ○ One anticonvulsant; or ○ One tricyclic antidepressant. 	Passed 10 For 1 Against
12	<p><u>First-Generation Antipsychotics</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent(s) based on economic evaluation; however, at least four unique chemical entities, at least one representing an agent from each of the potency groups, should be preferred. 2. Agents not selected as preferred will be considered non preferred and require prior authorization 3. Allow continuation of therapy for non preferred single source branded products via a 90 day look back. 4. For any new chemical entity in the First-Generation Antipsychotics class, require a PA until reviewed by the P&T Advisory Committee. 	Passed 11 For 0 Against
13	<p><u>Second-Generation Antipsychotics</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent(s) based on economic evaluation; however, at least five unique chemical entities, one of which must be lurasidone, should be preferred. 2. Require appropriate ICD-9 on all prescriptions for agents within this class. 3. Place quantity limits on all agents in the class. 4. Allow only two agents at a time unless switching agents due to therapeutic failure or the patient is refractory to dual therapy. 5. Allow continuation of therapy for non preferred single source branded products via a 90 day look back. 6. All products in the category should have a tier 1 copay regardless of preferred or non preferred status. 7. For any new chemical entity in the Second-Generation Antipsychotics class, require a PA until reviewed by the P&T Advisory Committee. 	Passed 11 For 0 Against

	Description of Recommendation	P & T Vote																														
14	<p><u>Second-Generation Antipsychotics Clinical Criteria</u> Preferred Second-Generation Antipsychotics will be allowed for the following diagnoses only.</p> <table border="1" data-bbox="302 415 1227 1892"> <thead> <tr> <th data-bbox="302 415 594 451">Approvable ICD-9</th> <th data-bbox="599 415 1227 451">Approvable Diagnosis Description</th> </tr> </thead> <tbody> <tr> <td colspan="2" data-bbox="302 457 1227 493">Schizophrenic disorders</td> </tr> <tr> <td data-bbox="302 499 594 562">295.00</td> <td data-bbox="599 499 1227 562">Simple Type Schizophrenia, Unspecified State Schizophrenia simplex</td> </tr> <tr> <td data-bbox="302 569 594 632">295.01</td> <td data-bbox="599 569 1227 632">Simple Type Schizophrenia, Subchronic State Schizophrenia simplex</td> </tr> <tr> <td data-bbox="302 638 594 701">295.02</td> <td data-bbox="599 638 1227 701">Simple Type Schizophrenia, Chronic State Schizophrenia simplex</td> </tr> <tr> <td data-bbox="302 707 594 812">295.03</td> <td data-bbox="599 707 1227 812">Simple Type Schizophrenia, Subchronic State With Acute Exacerbation Schizophrenia simplex</td> </tr> <tr> <td data-bbox="302 819 594 924">295.04</td> <td data-bbox="599 819 1227 924">Simple Type Schizophrenia, Chronic State With Acute Exacerbation Schizophrenia simplex</td> </tr> <tr> <td data-bbox="302 930 594 993">295.05</td> <td data-bbox="599 930 1227 993">Simple Type Schizophrenia, In Remission Schizophrenia simplex</td> </tr> <tr> <td data-bbox="302 999 594 1104">295.10</td> <td data-bbox="599 999 1227 1104">Disorganized Type Schizophrenia, Unspecified State Hebephrenia; Hebephrenic type schizophrenia</td> </tr> <tr> <td data-bbox="302 1110 594 1215">295.11</td> <td data-bbox="599 1110 1227 1215">Disorganized Type Schizophrenia, Subchronic State Hebephrenia; Hebephrenic type schizophrenia</td> </tr> <tr> <td data-bbox="302 1222 594 1327">295.12</td> <td data-bbox="599 1222 1227 1327">Disorganized Type Schizophrenia, Chronic State Hebephrenia; Hebephrenic type schizophrenia</td> </tr> <tr> <td data-bbox="302 1333 594 1438">295.13</td> <td data-bbox="599 1333 1227 1438">Disorganized Type Schizophrenia, Subchronic State With Acute Exacerbation Hebephrenia; Hebephrenic type schizophrenia</td> </tr> <tr> <td data-bbox="302 1444 594 1549">295.14</td> <td data-bbox="599 1444 1227 1549">Disorganized Type Schizophrenia, Chronic State With Acute Exacerbation Hebephrenia; Hebephrenic type schizophrenia</td> </tr> <tr> <td data-bbox="302 1556 594 1661">295.15</td> <td data-bbox="599 1556 1227 1661">Disorganized Type Schizophrenia, In Remission Hebephrenia; Hebephrenic type schizophrenia</td> </tr> <tr> <td data-bbox="302 1667 594 1892">295.20</td> <td data-bbox="599 1667 1227 1892">Catatonic Type Schizophrenia, Unspecified State Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea</td> </tr> </tbody> </table>	Approvable ICD-9	Approvable Diagnosis Description	Schizophrenic disorders		295.00	Simple Type Schizophrenia, Unspecified State Schizophrenia simplex	295.01	Simple Type Schizophrenia, Subchronic State Schizophrenia simplex	295.02	Simple Type Schizophrenia, Chronic State Schizophrenia simplex	295.03	Simple Type Schizophrenia, Subchronic State With Acute Exacerbation Schizophrenia simplex	295.04	Simple Type Schizophrenia, Chronic State With Acute Exacerbation Schizophrenia simplex	295.05	Simple Type Schizophrenia, In Remission Schizophrenia simplex	295.10	Disorganized Type Schizophrenia, Unspecified State Hebephrenia; Hebephrenic type schizophrenia	295.11	Disorganized Type Schizophrenia, Subchronic State Hebephrenia; Hebephrenic type schizophrenia	295.12	Disorganized Type Schizophrenia, Chronic State Hebephrenia; Hebephrenic type schizophrenia	295.13	Disorganized Type Schizophrenia, Subchronic State With Acute Exacerbation Hebephrenia; Hebephrenic type schizophrenia	295.14	Disorganized Type Schizophrenia, Chronic State With Acute Exacerbation Hebephrenia; Hebephrenic type schizophrenia	295.15	Disorganized Type Schizophrenia, In Remission Hebephrenia; Hebephrenic type schizophrenia	295.20	Catatonic Type Schizophrenia, Unspecified State Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea	<p>Passed 10 For 0 Against</p>
Approvable ICD-9	Approvable Diagnosis Description																															
Schizophrenic disorders																																
295.00	Simple Type Schizophrenia, Unspecified State Schizophrenia simplex																															
295.01	Simple Type Schizophrenia, Subchronic State Schizophrenia simplex																															
295.02	Simple Type Schizophrenia, Chronic State Schizophrenia simplex																															
295.03	Simple Type Schizophrenia, Subchronic State With Acute Exacerbation Schizophrenia simplex																															
295.04	Simple Type Schizophrenia, Chronic State With Acute Exacerbation Schizophrenia simplex																															
295.05	Simple Type Schizophrenia, In Remission Schizophrenia simplex																															
295.10	Disorganized Type Schizophrenia, Unspecified State Hebephrenia; Hebephrenic type schizophrenia																															
295.11	Disorganized Type Schizophrenia, Subchronic State Hebephrenia; Hebephrenic type schizophrenia																															
295.12	Disorganized Type Schizophrenia, Chronic State Hebephrenia; Hebephrenic type schizophrenia																															
295.13	Disorganized Type Schizophrenia, Subchronic State With Acute Exacerbation Hebephrenia; Hebephrenic type schizophrenia																															
295.14	Disorganized Type Schizophrenia, Chronic State With Acute Exacerbation Hebephrenia; Hebephrenic type schizophrenia																															
295.15	Disorganized Type Schizophrenia, In Remission Hebephrenia; Hebephrenic type schizophrenia																															
295.20	Catatonic Type Schizophrenia, Unspecified State Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea																															

295.21	Catatonic Type Schizophrenia, Subchronic State Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea
295.22	Catatonic Type Schizophrenia, Chronic State Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea
295.23	Catatonic Type Schizophrenia, Subchronic State With Acute Exacerbation Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea
295.24	Catatonic Type Schizophrenia, Chronic State With Acute Exacerbation Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea
295.25	Catatonic Type Schizophrenia, In Remission Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea
295.30	Paranoid Type Schizophrenia, Unspecified State Paraphrenic schizophrenia
295.31	Paranoid Type Schizophrenia, Subchronic State Paraphrenic schizophrenia
295.32	Paranoid Type Schizophrenia, Chronic State Paraphrenic schizophrenia
295.33	Paranoid Type Schizophrenia, Subchronic State With Acute Exacerbation Paraphrenic schizophrenia
295.34	Paranoid Type Schizophrenia, Chronic State With Acute Exacerbation Paraphrenic schizophrenia
295.35	Paranoid Type Schizophrenia, In Remission Paraphrenic schizophrenia
295.40	Schizophreniform Disorder, Unspecified State Oneirophrenia; Schizophreniform: attack,

		disorder, psychosis confusional type
295.41		Schizophreniform Disorder, Subchronic State Oneirophrenia; Schizophreniform: attack, disorder, psychosis confusional type
295.42		Schizophreniform Disorder, Chronic State Oneirophrenia; Schizophreniform: attack, disorder, psychosis confusional type
295.43		Schizophreniform Disorder, Subchronic State With Acute Exacerbation Oneirophrenia; Schizophreniform: attack, disorder, psychosis confusional type
295.44		Schizophreniform Disorder, Chronic State With Acute Exacerbation Oneirophrenia; Schizophreniform: attack, disorder, psychosis confusional type
295.45		Schizophreniform Disorder, In Remission Oneirophrenia; Schizophreniform: attack, disorder, psychosis confusional type
295.50		Latent Schizophrenia, Unspecified State Latent schizophrenic reaction; Schizophrenia: borderline, incipient, prepsychotic, prodromal, pseudoneurotic, pseudopsychopathic
295.51		Latent Schizophrenia, Subchronic State Latent schizophrenic reaction; Schizophrenia: borderline, incipient, prepsychotic, prodromal, pseudoneurotic, pseudopsychopathic
295.52		Latent Schizophrenia, Chronic State Latent schizophrenic reaction; Schizophrenia: borderline, incipient, prepsychotic, prodromal, pseudoneurotic, pseudopsychopathic
295.53		Latent Schizophrenia, Subchronic State With Acute Exacerbation Latent schizophrenic reaction; Schizophrenia: borderline, incipient, prepsychotic, prodromal, pseudoneurotic, pseudopsychopathic
295.54		Latent Schizophrenia, Chronic State With Acute Exacerbation Latent schizophrenic reaction; Schizophrenia: borderline, incipient, prepsychotic, prodromal, pseudoneurotic, pseudopsychopathic
295.55		Latent Schizophrenia, In Remission Latent schizophrenic reaction; Schizophrenia: borderline, incipient, prepsychotic, prodromal, pseudoneurotic, pseudopsychopathic
295.60		Residual Schizophrenia, Unspecified State Chronic undifferentiated schizophrenia;

	Restzustand (schizophrenic); Schizophrenic residual state
295.61	Residual Schizophrenia, Subchronic State Chronic undifferentiated schizophrenia; Restzustand (schizophrenic); Schizophrenic residual state
295.62	Residual Schizophrenia, Chronic State Chronic undifferentiated schizophrenia; Restzustand (schizophrenic); Schizophrenic residual state
295.63	Residual Schizophrenia, Subchronic State With Acute Exacerbation Chronic undifferentiated schizophrenia; Restzustand (schizophrenic); Schizophrenic residual state
295.64	Residual Schizophrenia, Chronic State With Acute Exacerbation Chronic undifferentiated schizophrenia; Restzustand (schizophrenic); Schizophrenic residual state
295.65	Residual Schizophrenia, In Remission Chronic undifferentiated schizophrenia; Restzustand (schizophrenic); Schizophrenic residual state
295.70	Schizoaffective Disorder, Unspecified State Cyclic schizophrenia; Mixed schizophrenic and affective psychosis; Schizo-affective psychosis; Schizophreniform psychosis, affective type
295.71	Schizoaffective Disorder, Subchronic State Cyclic schizophrenia; Mixed schizophrenic and affective psychosis; Schizo-affective psychosis; Schizophreniform psychosis, affective type
295.72	Schizoaffective Disorder, Chronic State Cyclic schizophrenia; Mixed schizophrenic and affective psychosis; Schizo-affective psychosis; Schizophreniform psychosis, affective type
295.73	Schizoaffective Disorder, Subchronic State With Acute Exacerbation Cyclic schizophrenia; Mixed schizophrenic and affective psychosis; Schizo-affective psychosis; Schizophreniform psychosis, affective type
295.74	Schizoaffective Disorder, Chronic State With

	Acute Exacerbation Cyclic schizophrenia; Mixed schizophrenic and affective psychosis; Schizo-affective psychosis; Schizophreniform psychosis, affective type
295.75	Schizoaffective Disorder, In Remission Cyclic schizophrenia; Mixed schizophrenic and affective psychosis; Schizo-affective psychosis; Schizophreniform psychosis, affective type
295.80	Other Specified Types Of Schizophrenia, Unspecified State Acute (undifferentiated) schizophrenia; Atypical schizophrenia; Cenesthopathic schizophrenia
295.81	Other Specified Types Of Schizophrenia, Subchronic State Acute (undifferentiated) schizophrenia; Atypical schizophrenia; Cenesthopathic schizophrenia
295.82	Other Specified Types Of Schizophrenia, Chronic State Acute (undifferentiated) schizophrenia; Atypical schizophrenia; Cenesthopathic schizophrenia
295.83	Other Specified Types Of Schizophrenia, Subchronic State With Acute Exacerbation Acute (undifferentiated) schizophrenia; Atypical schizophrenia; Cenesthopathic schizophrenia
295.84	Other Specified Types Of Schizophrenia, Chronic State With Acute Exacerbation Acute (undifferentiated) schizophrenia; Atypical schizophrenia; Cenesthopathic schizophrenia
295.85	Other Specified Types Of Schizophrenia, In Remission Acute (undifferentiated) schizophrenia; Atypical schizophrenia; Cenesthopathic schizophrenia
295.90	Unspecified Schizophrenia, Unspecified State Schizophrenia: NOS, mixed NOS, undifferentiated NOS; Schizophrenic reaction NOS; Schizophreniform psychosis NOS
295.91	Unspecified Schizophrenia, Subchronic State Schizophrenia: NOS, mixed NOS,

	undifferentiated NOS; Schizophrenic reaction NOS; Schizophreniform psychosis NOS
295.92	Unspecified Schizophrenia, Chronic State Schizophrenia: NOS, mixed NOS, undifferentiated NOS; Schizophrenic reaction NOS; Schizophreniform psychosis NOS
295.93	Unspecified Schizophrenia, Subchronic State With Acute Exacerbation Schizophrenia: NOS, mixed NOS, undifferentiated NOS; Schizophrenic reaction NOS; Schizophreniform psychosis NOS
295.94	Unspecified Schizophrenia, Chronic State With Acute Exacerbation Schizophrenia: NOS, mixed NOS, undifferentiated NOS; Schizophrenic reaction NOS; Schizophreniform psychosis NOS
295.95	Unspecified Schizophrenia, In Remission Schizophrenia: NOS, mixed NOS, undifferentiated NOS; Schizophrenic reaction NOS; Schizophreniform psychosis NOS
Episodic Mood Disorders	
296.00	Bipolar I Disorder, Single Manic Episode, Unspecified Degree {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.01	Bipolar I Disorder, Single Manic Episode, Mild Degree {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.02	Bipolar I Disorder, Single Manic Episode, Moderate Degree {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.03	Bipolar I Disorder, Single Manic Episode Severe Degree, Without Mention Of Psychotic Behavior {Hypomania (mild) NOS} {Hypomanic

	psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.04	Bipolar I Disorder, Single Manic Episode, Severe Degree, Specified As With Psychotic Behavior {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.05	Bipolar I Disorder, Single Manic Episode, In Partial Or Unspecified Remission {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.06	Bipolar I Disorder, Single Manic Episode, In Full Remission {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.10	Manic Disorder, Recurrent Episode, Unspecified Degree Any condition classifiable to 296.0, stated to be recurrent
296.11	Manic Disorder, Recurrent Episode, Mild Degree Any condition classifiable to 296.0, stated to be recurrent
296.12	Manic Disorder, Recurrent Episode, Moderate Degree Any condition classifiable to 296.0, stated to be recurrent
296.13	Manic Disorder, Recurrent Episode, Severe Degree, Without Mention Of Psychotic Behavior Any condition classifiable to 296.0, stated to be recurrent
296.14	Manic Disorder, Recurrent Episode, Severe Degree, Specified As With Psychotic Behavior Any condition classifiable to 296.0, stated to

		be recurrent
296.15	Manic Disorder, Recurrent Episode, In Partial Or Unspecified Remission Any condition classifiable to 296.0, stated to be recurrent	
296.16	Manic Disorder, Recurrent Episode, In Full Remission Any condition classifiable to 296.0, stated to be recurrent	
296.40	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, Unspecified Degree Bipolar disorder, now manic; Manic-depressive psychosis, circular type but currently manic	
296.41	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, Mild Degree Bipolar disorder, now manic; Manic-depressive psychosis, circular type but currently manic	
296.42	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, Moderate Degree Bipolar disorder, now manic; Manic-depressive psychosis, circular type but currently manic	
296.43	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, Severe Degree, Without Mention Of Psychotic Behavior Bipolar disorder, now manic Manic-depressive psychosis, circular type but currently manic	
296.44	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, Severe Degree, Specified As With Psychotic Behavior Bipolar disorder, now manic; Manic-depressive psychosis, circular type but currently manic	
296.45	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, In Partial Or Unspecified Remission Bipolar disorder, now manic; Manic-depressive psychosis, circular type but currently manic	
296.46	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, In Full Remission Bipolar disorder, now manic Manic-depressive psychosis, circular type but currently manic	
296.50	Bipolar I Disorder, Most Recent Episode (Or	

	Current) Depressed, Unspecified Degree Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.51	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, Mild Degree Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.52	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, Moderate Degree Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.53	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, Severe Degree, Without Mention Of Psychotic Behavior Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.54	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, Severe Degree, Specified As With Psychotic Behavior Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.55	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, In Partial Or Unspecified Remission Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.56	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, In Remission Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.60	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, Unspecified Degree Manic-depressive psychosis, circular type, mixed
296.61	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, Mild Degree Manic-depressive psychosis, circular type, mixed
296.62	Bipolar I Disorder, Most Recent Episode (Or

	Current) Mixed, Moderate Degree Manic-depressive psychosis, circular type, mixed
296.63	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, Severe Degree, Without Mention Of Psychotic Behavior Manic-depressive psychosis, circular type, mixed
296.64	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, Severe Degree, Specified As With Psychotic Behavior Manic-depressive psychosis, circular type, mixed
296.65	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, In Partial Or Unspecified Remission Manic-depressive psychosis, circular type, mixed
296.66	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, In Full Remission Manic-depressive psychosis, circular type, mixed
296.7	Bipolar I disorder, most recent episode 9or current0 unspecified
296.80	Bipolar Disorder, Unspecified Bipolar disorder NOS; Manic-depressive: reaction NOS, syndrome NOS
296.81	Atypical Manic Disorder
296.82	Atypical Depressive Disorder
296.89	Other Manic-depressive Psychosis Bipolar II Disorder; Manic-depressive psychosis, mixed type
296.90	Unspecified Episodic Mood Disorder Affective psychosis NOS; Melancholia NOS; Mood disorder NOS
296.99	Other Specified Episodic Mood Disorder Mood swings: brief compensatory, rebound
Delusional disorders	
297.0	Paranoid State, Simple
297.1	Delusional Disorder Chronic paranoid psychosis; Sander's disease; Systematized delusions
297.2	Paraphrenia Involuntional paranoid state; Late paraphrenia; Paraphrenia (involuntional)
297.3	Shared Psychotic Disorder

	Folie a deux; Induced psychosis or paranoid disorder
297.8	Other Specified Paranoid States Paranoia querulans; Sensitiver Beziehungswahn
297.9	Unspecified Paranoid State Paranoid: disorder NOS, psychosis NOS, reaction NOS, state NOS
298.0	Depressive Type Psychosis Psychogenic depressive psychosis; Psychotic reactive depression; Reactive depressive psychosis
298.1	Excitative Type Psychosis Acute hysterical psychosis; Psychogenic excitation; Reactive excitation
298.2	Reactive Confusion Psychogenic confusion; Psychogenic twilight state
298.3	Acute Paranoid Reaction Acute psychogenic paranoid psychosis; Bouffee delirante
298.4	Psychogenic Paranoid Psychosis Prolonged reactive paranoid psychosis
298.8	Other And Unspecified Reactive Psychosis Brief psychotic disorder; Brief reactive psychosis NOS; Hysterical psychosis; Psychogenic psychosis NOS; Psychogenic stupor
298.9	Unspecified Psychosis Atypical psychosis; Psychosis NOS; Psychotic disorder NOS
301.20	Schizoid Personality Disorder, Unspecified
301.21	Introverted Personality
301.22	Schizotypal Personality Disorder
Autism	
299.00	Autistic Disorder Childhood autism; Infantile psychosis; Kanner's syndrome
299.01	Autistic Disorder, Residual State Childhood autism; Infantile psychosis; Kanner's syndrome
299.10	Childhood Disintegrative Disorder, Current Or Active State Heller's syndrome
299.11	Childhood Disintegrative Disorder, Residual State

		Heller's syndrome	
299.80		Other Specified Pervasive Developmental Disorders, Current Or Active State Atypical childhood psychosis; Borderline psychosis of childhood	
299.81		Other Specified Pervasive Developmental Disorders, Residual State Atypical childhood psychosis; Borderline psychosis of childhood	
299.90		Unspecified Pervasive developmental disorder, Current Or Active State Child psychosis NOS; Schizophrenia, childhood type NOS; Schizophrenic syndrome of childhood NOS	
299.91		Unspecified Pervasive developmental disorder, Residual State Child psychosis NOS; Schizophrenia, childhood type NOS; Schizophrenic syndrome of childhood NOS	
		Dementias	
290.0		Senile Dementia, Uncomplicated Senile dementia: NOS, simple type	
290.10		Presenile Dementia, Uncomplicated Brain syndrome with presenile brain disease; Dementia in: Alzheimer's disease, Jakob-Creutzfeldt disease, Pick's disease of the brain; Presenile dementia: NOS, simple type	
290.11		Presenile Dementia, With Delirium Brain syndrome with presenile brain disease; Dementia in: Alzheimer's disease, Jakob-Creutzfeldt disease, Pick's disease of the brain; Presenile dementia with acute confusional state	
290.12		Presenile Dementia, With Delusional Features Brain syndrome with presenile brain disease; Dementia in: Alzheimer's disease, Jakob-Creutzfeldt disease, Pick's disease of the brain; Presenile dementia, paranoid type	
290.13		Presenile Dementia, With Depressive Features Brain syndrome with presenile brain disease; Dementia in: Alzheimer's disease, Jakob-Creutzfeldt disease, Pick's disease of the brain; Presenile dementia, depressed type	
290.20		Senile Dementia With Delusional Features Senile dementia, paranoid type; Senile psychosis NOS	

290.21	Senile Dementia With Depressive Features
290.3	Senile Dementia With Delirium Senile dementia with acute confusional state
290.40	Vascular Dementia, Uncomplicated Arteriosclerotic dementia: NOS, simple type; Multi-infarct dementia or psychosis
290.41	Vascular Dementia, With Delirium Arteriosclerotic dementia with acute confusional state; Multi-infarct dementia or psychosis
290.42	Vascular Dementia, With Delusions Arteriosclerotic dementia, paranoid type; Multi-infarct dementia or psychosis
290.43	Vascular Dementia, With Depressed Mood Arteriosclerotic dementia, depressed type; Multi-infarct dementia or psychosis
290.8	Other Specified Senile Psychotic Conditions Presbyophrenic psychosis
290.9	Unspecified Senile Psychotic Condition
Dissociative, Conversion And Factitious Disorders	
300.10	Hysteria, Unspecified
300.11	Conversion Disorder Astasia-abasia, hysterical; Conversion hysteria or reaction; Hysterical: blindness, deafness, paralysis
300.12	Dissociative Amnesia Hysterical amnesia
300.13	Dissociative Fugue Hysterical fugue
300.14	Dissociative Identity Disorder
300.15	Dissociative Disorder Or Reaction, Unspecified
300.16	Factitious Disorder With Predominantly Psychological Signs And Symptoms Compensation neurosis; Ganser's syndrome, hysterical
300.19	Other And Unspecified Factitious Illness Factitious Disorder (with combined psychological and physical signs and symptoms) (with predominantly physical signs and symptoms) NOS
Other	
292.11	Drug-Induced Psychotic Disorder With Delusions Paranoid state induced by drugs
292.12	Drug-Induced Psychotic Disorder With

	Hallucinations Hallucinatory state induced by drugs
293.81	Psychotic Disorder With Delusions In Conditions Classified Elsewhere Transient organic psychotic condition, paranoid type
293.82	Psychotic Disorder With Hallucinations In Conditions Classified Elsewhere Transient organic psychotic condition, hallucinatory type
307.20	Tic Disorder, Unspecified Tic disorder NOS
307.21	Transient Tic Disorder
307.22	Chronic Motor Or Vocal Tic Disorder
307.23	Tourette's Disorder Motor-verbal tic disorder
313.81	Oppositional Defiant Disorder Of Childhood Or Adolescence
333.4	Huntington's Chorea

*Non preferred Second-Generation Antipsychotics will be approved after a 2-week trial of ONE preferred Second-Generation Antipsychotic at an appropriate dose. If Invega® is selected as non preferred, approval will be granted if one of the following is true:

- Trial and failure of risperidone; OR
- Patient has hepatic impairment evident by elevated liver enzymes or a diagnosis suggestive of hepatic impairment.

**For a diagnosis not specifically mentioned above, a Second-Generation Antipsychotic may be approved if the prescriber can provide documented clinical evidence (peer reviewed literature or multiple case studies) supporting the use of the requested medication for the requested indication.

Major Depressive Disorder (MDD) Criteria:
Second-Generation Antipsychotics will be approved for MDD as adjunct therapy ONLY. Second-Generation Antipsychotics will be approved if any ONE of the following is true:

- An adequate trial (4 weeks) of at least one agent in two of the following classes of antidepressants (unless contraindicated or intolerant to):
 - Selective Serotonins Reuptake Inhibitor (SSRIs)
 - Serotonin-Norepinephrine Reuptake Inhibitor (SNRIs)
 - New Generation Antidepressants
 - Tricyclic antidepressants (TCAs); OR
- A diagnosis of Major Depressive Disorder (MDD) with psychotic features.

Multiple Agents Criteria:

Patients who are on more than 2 Second-Generation Antipsychotic agents will require PA. Approval will be granted for the following reasons:

- A maximum of 2 months to allow patients to taper to dual therapy.
- Additional agents may be added to existing dual therapy after a 2-week trial at the maximum tolerated dose of each agent.

Proposed Quantity Limits:

Drug	Strength	Per Day Count
Abilify [®]	All Strengths	1 per day (30 mg per day max)
Abilify Discmelt [®]	All Strengths	2 per day (30 mg per day max)
Abilify [®] oral solution	1mg/mL	30 mL per day (30 mg per day max)
Clozaril [®] / clozapine	25 mg	3 per day (900 mg per day max)
	50 mg	3 per day (900 mg per day max)
	100 mg	9 per day (900 mg per day max)
	200 mg	4 per day (900 mg per day max)
Fanapt [™]	All Strengths	2 per day (24 mg per day max)
FazaClo ODT [®] / clozapine	12.5 mg	3 per day (900 mg per day max)
	25 mg	3 per day (900 mg per day max)
	100 mg	9 per day (900 mg per day max)
	150 mg	6 per day (900 mg per day max)
	200 mg	4 per day (900 mg per day max)
Geodon [®] / ziprasidone	All Strengths	2 per day (160 mg per day max)
Invega [®]	1.5 mg	1 per day (12 mg per day max)
	3 mg	1 per day (12 mg per day max)
	6 mg	2 per day (12 mg per day max)
	9 mg	1 per day (12 mg per day max)
Latuda [®]	20 mg	1 per day (160 mg per day max)
	40 mg	1 per day (160 mg per day max)
	80 mg	2 per day (160 mg per day max)
	120 mg	1 per day (160 mg per day max)
Risperdal [®] / risperidone	All Strengths	2 per day (8 mg per day max)
Risperdal [®] / risperidone oral solution	1 mg/mL	8 mL per day (8 mg per day max)
Saphris [®]	All Strengths	2 per day (20 mg per day max)

	Seroquel [®] / quetiapine	25 mg	3 per day (800 mg per day max)	
		50 mg	3 per day (800 mg per day max)	
		100 mg	3 per day (800 mg per day max)	
		200 mg	3 per day (800 mg per day max)	
		300 mg	2 per day (800 mg per day max)	
		400 mg	2 per day (800 mg per day max)	
	Seroquel XR [®]	50 mg	2 per day (800 mg per day max)	
		150 mg	1 per day (800 mg per day max)	
		200 mg	1 per day (800 mg per day max)	
		300 mg	2 per day (800 mg per day max)	
		400 mg	2 per day (800 mg per day max)	
Zyprexa [®] / Zyprexa Zydis [®] / olanzapine	All Strengths	1 per day		
15	<u>Injectable Antipsychotics</u>		Passed	
	<ol style="list-style-type: none"> 1. DMS to select preferred agent(s) based on economic evaluation. Generic formulations of first generation injectable antipsychotics should be preferred. Additionally, two unique second generation injectable antipsychotics, one of which should have a duration of action of 2 weeks or longer, should be preferred. 2. Require appropriate ICD-9 on all prescriptions for agents within this class. 3. Allow only two agents at a time unless switching agents due to therapeutic failure or the patient is refractory to dual therapy. 4. Allow continuation of therapy for non preferred single source branded products via a 90 day look back. 5. All products in the category should have a tier 1 copay regardless of preferred or non preferred status. 6. For any new chemical entity in the Injectable Antipsychotics class, require a PA until reviewed by the P&T Advisory Committee. 		10 For 0 Against	

	Description of Recommendation	P & T Vote																														
16	<p><u>Injectable Antipsychotics Clinical Criteria</u> Preferred Injectable Antipsychotics will be allowed for the following diagnoses only.</p> <table border="1" data-bbox="302 411 1229 1892"> <thead> <tr> <th data-bbox="302 411 597 449">Approvable ICD-9</th> <th data-bbox="604 411 1229 449">Approvable Diagnosis Description</th> </tr> </thead> <tbody> <tr> <td colspan="2" data-bbox="302 453 1229 491" style="text-align: center;">Schizophrenic disorders</td> </tr> <tr> <td data-bbox="302 495 597 562">295.00</td> <td data-bbox="604 495 1229 562">Simple Type Schizophrenia, Unspecified State Schizophrenia simplex</td> </tr> <tr> <td data-bbox="302 567 597 634">295.01</td> <td data-bbox="604 567 1229 634">Simple Type Schizophrenia, Subchronic State Schizophrenia simplex</td> </tr> <tr> <td data-bbox="302 638 597 705">295.02</td> <td data-bbox="604 638 1229 705">Simple Type Schizophrenia, Chronic State Schizophrenia simplex</td> </tr> <tr> <td data-bbox="302 709 597 823">295.03</td> <td data-bbox="604 709 1229 823">Simple Type Schizophrenia, Subchronic State With Acute Exacerbation Schizophrenia simplex</td> </tr> <tr> <td data-bbox="302 827 597 940">295.04</td> <td data-bbox="604 827 1229 940">Simple Type Schizophrenia, Chronic State With Acute Exacerbation Schizophrenia simplex</td> </tr> <tr> <td data-bbox="302 945 597 1012">295.05</td> <td data-bbox="604 945 1229 1012">Simple Type Schizophrenia, In Remission Schizophrenia simplex</td> </tr> <tr> <td data-bbox="302 1016 597 1129">295.10</td> <td data-bbox="604 1016 1229 1129">Disorganized Type Schizophrenia, Unspecified State Hebephrenia; Hebephrenic type schizophrenia</td> </tr> <tr> <td data-bbox="302 1134 597 1247">295.11</td> <td data-bbox="604 1134 1229 1247">Disorganized Type Schizophrenia, Subchronic State Hebephrenia; Hebephrenic type schizophrenia</td> </tr> <tr> <td data-bbox="302 1251 597 1365">295.12</td> <td data-bbox="604 1251 1229 1365">Disorganized Type Schizophrenia, Chronic State Hebephrenia; Hebephrenic type schizophrenia</td> </tr> <tr> <td data-bbox="302 1369 597 1482">295.13</td> <td data-bbox="604 1369 1229 1482">Disorganized Type Schizophrenia, Subchronic State With Acute Exacerbation Hebephrenia; Hebephrenic type schizophrenia</td> </tr> <tr> <td data-bbox="302 1486 597 1600">295.14</td> <td data-bbox="604 1486 1229 1600">Disorganized Type Schizophrenia, Chronic State With Acute Exacerbation Hebephrenia; Hebephrenic type schizophrenia</td> </tr> <tr> <td data-bbox="302 1604 597 1717">295.15</td> <td data-bbox="604 1604 1229 1717">Disorganized Type Schizophrenia, In Remission Hebephrenia; Hebephrenic type schizophrenia</td> </tr> <tr> <td data-bbox="302 1722 597 1892">295.20</td> <td data-bbox="604 1722 1229 1892">Catatonic Type Schizophrenia, Unspecified State Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea</td> </tr> </tbody> </table>	Approvable ICD-9	Approvable Diagnosis Description	Schizophrenic disorders		295.00	Simple Type Schizophrenia, Unspecified State Schizophrenia simplex	295.01	Simple Type Schizophrenia, Subchronic State Schizophrenia simplex	295.02	Simple Type Schizophrenia, Chronic State Schizophrenia simplex	295.03	Simple Type Schizophrenia, Subchronic State With Acute Exacerbation Schizophrenia simplex	295.04	Simple Type Schizophrenia, Chronic State With Acute Exacerbation Schizophrenia simplex	295.05	Simple Type Schizophrenia, In Remission Schizophrenia simplex	295.10	Disorganized Type Schizophrenia, Unspecified State Hebephrenia; Hebephrenic type schizophrenia	295.11	Disorganized Type Schizophrenia, Subchronic State Hebephrenia; Hebephrenic type schizophrenia	295.12	Disorganized Type Schizophrenia, Chronic State Hebephrenia; Hebephrenic type schizophrenia	295.13	Disorganized Type Schizophrenia, Subchronic State With Acute Exacerbation Hebephrenia; Hebephrenic type schizophrenia	295.14	Disorganized Type Schizophrenia, Chronic State With Acute Exacerbation Hebephrenia; Hebephrenic type schizophrenia	295.15	Disorganized Type Schizophrenia, In Remission Hebephrenia; Hebephrenic type schizophrenia	295.20	Catatonic Type Schizophrenia, Unspecified State Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea	<p>Passed 10 For 0 Against</p>
Approvable ICD-9	Approvable Diagnosis Description																															
Schizophrenic disorders																																
295.00	Simple Type Schizophrenia, Unspecified State Schizophrenia simplex																															
295.01	Simple Type Schizophrenia, Subchronic State Schizophrenia simplex																															
295.02	Simple Type Schizophrenia, Chronic State Schizophrenia simplex																															
295.03	Simple Type Schizophrenia, Subchronic State With Acute Exacerbation Schizophrenia simplex																															
295.04	Simple Type Schizophrenia, Chronic State With Acute Exacerbation Schizophrenia simplex																															
295.05	Simple Type Schizophrenia, In Remission Schizophrenia simplex																															
295.10	Disorganized Type Schizophrenia, Unspecified State Hebephrenia; Hebephrenic type schizophrenia																															
295.11	Disorganized Type Schizophrenia, Subchronic State Hebephrenia; Hebephrenic type schizophrenia																															
295.12	Disorganized Type Schizophrenia, Chronic State Hebephrenia; Hebephrenic type schizophrenia																															
295.13	Disorganized Type Schizophrenia, Subchronic State With Acute Exacerbation Hebephrenia; Hebephrenic type schizophrenia																															
295.14	Disorganized Type Schizophrenia, Chronic State With Acute Exacerbation Hebephrenia; Hebephrenic type schizophrenia																															
295.15	Disorganized Type Schizophrenia, In Remission Hebephrenia; Hebephrenic type schizophrenia																															
295.20	Catatonic Type Schizophrenia, Unspecified State Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea																															

295.21	Catatonic Type Schizophrenia, Subchronic State Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea
295.22	Catatonic Type Schizophrenia, Chronic State Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea
295.23	Catatonic Type Schizophrenia, Subchronic State With Acute Exacerbation Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea
295.24	Catatonic Type Schizophrenia, Chronic State With Acute Exacerbation Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea
295.25	Catatonic Type Schizophrenia, In Remission Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea
295.30	Paranoid Type Schizophrenia, Unspecified State Paraphrenic schizophrenia
295.31	Paranoid Type Schizophrenia, Subchronic State Paraphrenic schizophrenia
295.32	Paranoid Type Schizophrenia, Chronic State Paraphrenic schizophrenia
295.33	Paranoid Type Schizophrenia, Subchronic State With Acute Exacerbation Paraphrenic schizophrenia
295.34	Paranoid Type Schizophrenia, Chronic State With Acute Exacerbation Paraphrenic schizophrenia
295.35	Paranoid Type Schizophrenia, In Remission Paraphrenic schizophrenia
295.40	Schizophreniform Disorder, Unspecified State Oneirophrenia; Schizophreniform: attack,

		disorder, psychosis confusional type
295.41		Schizophreniform Disorder, Subchronic State Oneirophrenia; Schizophreniform: attack, disorder, psychosis confusional type
295.42		Schizophreniform Disorder, Chronic State Oneirophrenia; Schizophreniform: attack, disorder, psychosis confusional type
295.43		Schizophreniform Disorder, Subchronic State With Acute Exacerbation Oneirophrenia; Schizophreniform: attack, disorder, psychosis confusional type
295.44		Schizophreniform Disorder, Chronic State With Acute Exacerbation Oneirophrenia; Schizophreniform: attack, disorder, psychosis confusional type
295.45		Schizophreniform Disorder, In Remission Oneirophrenia; Schizophreniform: attack, disorder, psychosis confusional type
295.50		Latent Schizophrenia, Unspecified State Latent schizophrenic reaction; Schizophrenia: borderline, incipient, prepsychotic, prodromal, pseudoneurotic, pseudopsychopathic
295.51		Latent Schizophrenia, Subchronic State Latent schizophrenic reaction; Schizophrenia: borderline, incipient, prepsychotic, prodromal, pseudoneurotic, pseudopsychopathic
295.52		Latent Schizophrenia, Chronic State Latent schizophrenic reaction; Schizophrenia: borderline, incipient, prepsychotic, prodromal, pseudoneurotic, pseudopsychopathic
295.53		Latent Schizophrenia, Subchronic State With Acute Exacerbation Latent schizophrenic reaction; Schizophrenia: borderline, incipient, prepsychotic, prodromal, pseudoneurotic, pseudopsychopathic
295.54		Latent Schizophrenia, Chronic State With Acute Exacerbation Latent schizophrenic reaction; Schizophrenia: borderline, incipient, prepsychotic, prodromal, pseudoneurotic, pseudopsychopathic
295.55		Latent Schizophrenia, In Remission Latent schizophrenic reaction; Schizophrenia: borderline, incipient, prepsychotic, prodromal, pseudoneurotic, pseudopsychopathic
295.60		Residual Schizophrenia, Unspecified State Chronic undifferentiated schizophrenia;

	Restzustand (schizophrenic); Schizophrenic residual state
295.61	Residual Schizophrenia, Subchronic State Chronic undifferentiated schizophrenia; Restzustand (schizophrenic); Schizophrenic residual state
295.62	Residual Schizophrenia, Chronic State Chronic undifferentiated schizophrenia; Restzustand (schizophrenic); Schizophrenic residual state
295.63	Residual Schizophrenia, Subchronic State With Acute Exacerbation Chronic undifferentiated schizophrenia; Restzustand (schizophrenic); Schizophrenic residual state
295.64	Residual Schizophrenia, Chronic State With Acute Exacerbation Chronic undifferentiated schizophrenia; Restzustand (schizophrenic); Schizophrenic residual state
295.65	Residual Schizophrenia, In Remission Chronic undifferentiated schizophrenia; Restzustand (schizophrenic); Schizophrenic residual state
295.70	Schizoaffective Disorder, Unspecified State Cyclic schizophrenia; Mixed schizophrenic and affective psychosis; Schizo-affective psychosis; Schizophreniform psychosis, affective type
295.71	Schizoaffective Disorder, Subchronic State Cyclic schizophrenia; Mixed schizophrenic and affective psychosis; Schizo-affective psychosis; Schizophreniform psychosis, affective type
295.72	Schizoaffective Disorder, Chronic State Cyclic schizophrenia; Mixed schizophrenic and affective psychosis; Schizo-affective psychosis; Schizophreniform psychosis, affective type
295.73	Schizoaffective Disorder, Subchronic State With Acute Exacerbation Cyclic schizophrenia; Mixed schizophrenic and affective psychosis; Schizo-affective psychosis; Schizophreniform psychosis, affective type
295.74	Schizoaffective Disorder, Chronic State With

	Acute Exacerbation Cyclic schizophrenia; Mixed schizophrenic and affective psychosis; Schizo-affective psychosis; Schizophreniform psychosis, affective type
295.75	Schizoaffective Disorder, In Remission Cyclic schizophrenia; Mixed schizophrenic and affective psychosis; Schizo-affective psychosis; Schizophreniform psychosis, affective type
295.80	Other Specified Types Of Schizophrenia, Unspecified State Acute (undifferentiated) schizophrenia; Atypical schizophrenia; Cenesthopathic schizophrenia
295.81	Other Specified Types Of Schizophrenia, Subchronic State Acute (undifferentiated) schizophrenia; Atypical schizophrenia; Cenesthopathic schizophrenia
295.82	Other Specified Types Of Schizophrenia, Chronic State Acute (undifferentiated) schizophrenia; Atypical schizophrenia; Cenesthopathic schizophrenia
295.83	Other Specified Types Of Schizophrenia, Subchronic State With Acute Exacerbation Acute (undifferentiated) schizophrenia; Atypical schizophrenia; Cenesthopathic schizophrenia
295.84	Other Specified Types Of Schizophrenia, Chronic State With Acute Exacerbation Acute (undifferentiated) schizophrenia; Atypical schizophrenia; Cenesthopathic schizophrenia
295.85	Other Specified Types Of Schizophrenia, In Remission Acute (undifferentiated) schizophrenia; Atypical schizophrenia; Cenesthopathic schizophrenia
295.90	Unspecified Schizophrenia, Unspecified State Schizophrenia: NOS, mixed NOS, undifferentiated NOS; Schizophrenic reaction NOS; Schizophreniform psychosis NOS
295.91	Unspecified Schizophrenia, Subchronic State Schizophrenia: NOS, mixed NOS,

	undifferentiated NOS; Schizophrenic reaction NOS; Schizophreniform psychosis NOS
295.92	Unspecified Schizophrenia, Chronic State Schizophrenia: NOS, mixed NOS, undifferentiated NOS; Schizophrenic reaction NOS; Schizophreniform psychosis NOS
295.93	Unspecified Schizophrenia, Subchronic State With Acute Exacerbation Schizophrenia: NOS, mixed NOS, undifferentiated NOS; Schizophrenic reaction NOS; Schizophreniform psychosis NOS
295.94	Unspecified Schizophrenia, Chronic State With Acute Exacerbation Schizophrenia: NOS, mixed NOS, undifferentiated NOS; Schizophrenic reaction NOS; Schizophreniform psychosis NOS
295.95	Unspecified Schizophrenia, In Remission Schizophrenia: NOS, mixed NOS, undifferentiated NOS; Schizophrenic reaction NOS; Schizophreniform psychosis NOS
Episodic Mood Disorders	
296.00	Bipolar I Disorder, Single Manic Episode, Unspecified Degree {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.01	Bipolar I Disorder, Single Manic Episode, Mild Degree {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.02	Bipolar I Disorder, Single Manic Episode, Moderate Degree {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.03	Bipolar I Disorder, Single Manic Episode Severe Degree, Without Mention Of Psychotic Behavior {Hypomania (mild) NOS} {Hypomanic

	psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.04	Bipolar I Disorder, Single Manic Episode, Severe Degree, Specified As With Psychotic Behavior {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.05	Bipolar I Disorder, Single Manic Episode, In Partial Or Unspecified Remission {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.06	Bipolar I Disorder, Single Manic Episode, In Full Remission {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.10	Manic Disorder, Recurrent Episode, Unspecified Degree Any condition classifiable to 296.0, stated to be recurrent
296.11	Manic Disorder, Recurrent Episode, Mild Degree Any condition classifiable to 296.0, stated to be recurrent
296.12	Manic Disorder, Recurrent Episode, Moderate Degree Any condition classifiable to 296.0, stated to be recurrent
296.13	Manic Disorder, Recurrent Episode, Severe Degree, Without Mention Of Psychotic Behavior Any condition classifiable to 296.0, stated to be recurrent
296.14	Manic Disorder, Recurrent Episode, Severe Degree, Specified As With Psychotic Behavior Any condition classifiable to 296.0, stated to

		be recurrent
296.15	Manic Disorder, Recurrent Episode, In Partial Or Unspecified Remission Any condition classifiable to 296.0, stated to be recurrent	
296.16	Manic Disorder, Recurrent Episode, In Full Remission Any condition classifiable to 296.0, stated to be recurrent	
296.40	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, Unspecified Degree Bipolar disorder, now manic; Manic-depressive psychosis, circular type but currently manic	
296.41	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, Mild Degree Bipolar disorder, now manic; Manic-depressive psychosis, circular type but currently manic	
296.42	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, Moderate Degree Bipolar disorder, now manic; Manic-depressive psychosis, circular type but currently manic	
296.43	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, Severe Degree, Without Mention Of Psychotic Behavior Bipolar disorder, now manic Manic-depressive psychosis, circular type but currently manic	
296.44	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, Severe Degree, Specified As With Psychotic Behavior Bipolar disorder, now manic; Manic-depressive psychosis, circular type but currently manic	
296.45	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, In Partial Or Unspecified Remission Bipolar disorder, now manic; Manic-depressive psychosis, circular type but currently manic	
296.46	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, In Full Remission Bipolar disorder, now manic Manic-depressive psychosis, circular type but currently manic	
296.50	Bipolar I Disorder, Most Recent Episode (Or	

	Current) Depressed, Unspecified Degree Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.51	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, Mild Degree Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.52	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, Moderate Degree Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.53	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, Severe Degree, Without Mention Of Psychotic Behavior Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.54	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, Severe Degree, Specified As With Psychotic Behavior Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.55	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, In Partial Or Unspecified Remission Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.56	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, In Remission Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.60	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, Unspecified Degree Manic-depressive psychosis, circular type, mixed
296.61	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, Mild Degree Manic-depressive psychosis, circular type, mixed
296.62	Bipolar I Disorder, Most Recent Episode (Or

	Current) Mixed, Moderate Degree Manic-depressive psychosis, circular type, mixed
296.63	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, Severe Degree, Without Mention Of Psychotic Behavior Manic-depressive psychosis, circular type, mixed
296.64	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, Severe Degree, Specified As With Psychotic Behavior Manic-depressive psychosis, circular type, mixed
296.65	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, In Partial Or Unspecified Remission Manic-depressive psychosis, circular type, mixed
296.66	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, In Full Remission Manic-depressive psychosis, circular type, mixed
296.7	Bipolar I disorder, most recent episode 9or current0 unspecified
296.80	Bipolar Disorder, Unspecified Bipolar disorder NOS; Manic-depressive: reaction NOS, syndrome NOS
296.81	Atypical Manic Disorder
296.82	Atypical Depressive Disorder
296.89	Other Manic-depressive Psychosis Bipolar II Disorder; Manic-depressive psychosis, mixed type
296.90	Unspecified Episodic Mood Disorder Affective psychosis NOS; Melancholia NOS; Mood disorder NOS
296.99	Other Specified Episodic Mood Disorder Mood swings: brief compensatory, rebound
Delusional disorders	
297.0	Paranoid State, Simple
297.1	Delusional Disorder Chronic paranoid psychosis; Sander's disease; Systematized delusions
297.2	Paraphrenia Involuntional paranoid state; Late paraphrenia; Paraphrenia (involuntional)
297.3	Shared Psychotic Disorder

	Folie a deux; Induced psychosis or paranoid disorder
297.8	Other Specified Paranoid States Paranoia querulans; Sensitiver Beziehungswahn
297.9	Unspecified Paranoid State Paranoid: disorder NOS, psychosis NOS, reaction NOS, state NOS
298.0	Depressive Type Psychosis Psychogenic depressive psychosis; Psychotic reactive depression; Reactive depressive psychosis
298.1	Excitative Type Psychosis Acute hysterical psychosis; Psychogenic excitation; Reactive excitation
298.2	Reactive Confusion Psychogenic confusion; Psychogenic twilight state
298.3	Acute Paranoid Reaction Acute psychogenic paranoid psychosis; Bouffee delirante
298.4	Psychogenic Paranoid Psychosis Protracted reactive paranoid psychosis
298.8	Other And Unspecified Reactive Psychosis Brief psychotic disorder; Brief reactive psychosis NOS; Hysterical psychosis; Psychogenic psychosis NOS; Psychogenic stupor
298.9	Unspecified Psychosis Atypical psychosis; Psychosis NOS; Psychotic disorder NOS
301.20	Schizoid Personality Disorder, Unspecified
301.21	Introverted Personality
301.22	Schizotypal Personality Disorder
Autism	
299.00	Autistic Disorder Childhood autism; Infantile psychosis; Kanner's syndrome
299.01	Autistic Disorder, Residual State Childhood autism; Infantile psychosis; Kanner's syndrome
299.10	Childhood Disintegrative Disorder, Current Or Active State Heller's syndrome
299.11	Childhood Disintegrative Disorder, Residual State

		Heller's syndrome	
299.80		Other Specified Pervasive Developmental Disorders, Current Or Active State Atypical childhood psychosis; Borderline psychosis of childhood	
299.81		Other Specified Pervasive Developmental Disorders, Residual State Atypical childhood psychosis; Borderline psychosis of childhood	
299.90		Unspecified Pervasive developmental disorder, Current Or Active State Child psychosis NOS; Schizophrenia, childhood type NOS; Schizophrenic syndrome of childhood NOS	
299.91		Unspecified Pervasive developmental disorder, Residual State Child psychosis NOS; Schizophrenia, childhood type NOS; Schizophrenic syndrome of childhood NOS	
		Dementias	
290.0		Senile Dementia, Uncomplicated Senile dementia: NOS, simple type	
290.10		Presenile Dementia, Uncomplicated Brain syndrome with presenile brain disease; Dementia in: Alzheimer's disease, Jakob-Creutzfeldt disease, Pick's disease of the brain; Presenile dementia: NOS, simple type	
290.11		Presenile Dementia, With Delirium Brain syndrome with presenile brain disease; Dementia in: Alzheimer's disease, Jakob-Creutzfeldt disease, Pick's disease of the brain; Presenile dementia with acute confusional state	
290.12		Presenile Dementia, With Delusional Features Brain syndrome with presenile brain disease; Dementia in: Alzheimer's disease, Jakob-Creutzfeldt disease, Pick's disease of the brain; Presenile dementia, paranoid type	
290.13		Presenile Dementia, With Depressive Features Brain syndrome with presenile brain disease; Dementia in: Alzheimer's disease, Jakob-Creutzfeldt disease, Pick's disease of the brain; Presenile dementia, depressed type	
290.20		Senile Dementia With Delusional Features Senile dementia, paranoid type; Senile psychosis NOS	

290.21	Senile Dementia With Depressive Features
290.3	Senile Dementia With Delirium Senile dementia with acute confusional state
290.40	Vascular Dementia, Uncomplicated Arteriosclerotic dementia: NOS, simple type; Multi-infarct dementia or psychosis
290.41	Vascular Dementia, With Delirium Arteriosclerotic dementia with acute confusional state; Multi-infarct dementia or psychosis
290.42	Vascular Dementia, With Delusions Arteriosclerotic dementia, paranoid type; Multi-infarct dementia or psychosis
290.43	Vascular Dementia, With Depressed Mood Arteriosclerotic dementia, depressed type; Multi-infarct dementia or psychosis
290.8	Other Specified Senile Psychotic Conditions Presbyophrenic psychosis
290.9	Unspecified Senile Psychotic Condition
Dissociative, Conversion And Factitious Disorders	
300.10	Hysteria, Unspecified
300.11	Conversion Disorder Astasia-abasia, hysterical; Conversion hysteria or reaction; Hysterical: blindness, deafness, paralysis
300.12	Dissociative Amnesia Hysterical amnesia
300.13	Dissociative Fugue Hysterical fugue
300.14	Dissociative Identity Disorder
300.15	Dissociative Disorder Or Reaction, Unspecified
300.16	Factitious Disorder With Predominantly Psychological Signs And Symptoms Compensation neurosis; Ganser's syndrome, hysterical
300.19	Other And Unspecified Factitious Illness Factitious Disorder (with combined psychological and physical signs and symptoms) (with predominantly physical signs and symptoms) NOS
Other	
292.11	Drug-Induced Psychotic Disorder With Delusions Paranoid state induced by drugs
292.12	Drug-Induced Psychotic Disorder With

	Hallucinations Hallucinatory state induced by drugs
293.81	Psychotic Disorder With Delusions In Conditions Classified Elsewhere Transient organic psychotic condition, paranoid type
293.82	Psychotic Disorder With Hallucinations In Conditions Classified Elsewhere Transient organic psychotic condition, hallucinatory type
307.20	Tic Disorder, Unspecified Tic disorder NOS
307.21	Transient Tic Disorder
307.22	Chronic Motor Or Vocal Tic Disorder
307.23	Tourette's Disorder Motor-verbal tic disorder
313.81	Oppositional Defiant Disorder Of Childhood Or Adolescence
333.4	Huntington's Chorea

*Non preferred Injectable Antipsychotics will be approved after a 2-week trial of ONE preferred Antipsychotic (oral or parenteral) at an appropriate dose. If Invega® Sustenna® is selected as non preferred, approval will be granted if one of the following is true:

- Trial and failure of risperidone; OR
- Patient has hepatic impairment evident by elevated liver enzymes or a diagnosis suggestive of hepatic impairment

**For a diagnosis not specifically mentioned above, an injectable antipsychotic may be approved if the prescriber can provide documented clinical evidence (peer reviewed literature or multiple case studies) supporting the use of the requested medication for the requested indication.

Multiple Therapy Criteria:
Patients who are on more than two Second-Generation Antipsychotic agents will require PA. Approval will be granted for the following reasons:

- A maximum of 2 months to allow patients to taper to dual therapy.
- Additional agents may be added to existing dual therapy after a 2-week trial at the maximum tolerated dose if each agent.

Proposed Quantity Limits:		
Drug	Strength	Per Day Count
Abilify [®]	9.7 mg/1.3 mL	1.3 mL per day
fluphenazine decanoate	25 mg/mL	4 mL per month
haloperidol decanoate / Haldol [®] Decanoate	50 mg/mL	1 mL per month
	100 mg/mL	2 mL per month
Zyprexa [®]	10 mg	30 mg per RX
Zyprexa [®] Relprevv	210 mg	210 mg every 2 weeks
	300 mg	300 mg every 2 weeks
	405 mg	405 mg every 4 weeks
Invega [®] Sustenna [™]	39 mg/0.25 mL	0.25 mL per month
	78 mg/0.5 mL	0.5 mL per month
	117 mg/0.75 mL	0.75 mL per month
	156 mg/1 mL	1 mL per month
	234 mg/1.5mL	1.5 mL per month
Risperdal [®] Consta [®]	12.5 mg	12.5 mg every 2 weeks
	25 mg	25 mg every 2 weeks
	37.5 mg	37.5 mg every 2 weeks
	50 mg	50 mg every 2 weeks
Geodon [®]	20 mg	40 mg per RX
17	<p><u>Second-Generation Antipsychotic and SSRI Combinations</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent(s) based on economic evaluation. 2. Require prior authorization and quantity limits for agents in this class. 3. Require prior authorization if this product is being used with more than one other second-generation antipsychotic unless switching agents due to therapeutic failure or the patient is refractory to dual second-generation antipsychotic therapy. 4. Allow continuation of therapy for non preferred single source branded products via a 90 day look back. 5. For any new chemical entity in the Second-Generation Antipsychotic and SSRI Combination class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed 10 For 0 Against</p>

	Description of Recommendation	P & T Vote									
18	<p><u>Second-Generation Antipsychotic and SSRI Combinations Clinical Criteria</u></p> <p>Olanzapine/fluoxetine will be approved if ONE of the following is true:</p> <ul style="list-style-type: none"> • Diagnosis of depressive episodes associated with bipolar disorder after trial and failure of ONE of the following: <ul style="list-style-type: none"> ○ Lithium; OR ○ Lamotrigine; OR ○ Bupropion; OR ○ Paroxetine. • Diagnosis of treatment-resistant depression after trial and failure of one agent from THREE of the following classes of medications: <ul style="list-style-type: none"> ○ SSRI; ○ SNRI; ○ New Generation Antidepressant; ○ Tricyclic Antidepressant; ○ MAOI. <p>**For a diagnosis not specifically mentioned above, olanzapine/fluoxetine may be approved if the prescriber can provide documented clinical evidence (peer reviewed literature or multiple case studies) supporting the use of the requested medication for the requested indication.</p> <p>Multiple Therapy Criteria:</p> <p>Patients who are on more than 2 Second-Generation Antipsychotic agents will require PA. Approval will be granted for the following reasons:</p> <ul style="list-style-type: none"> • A maximum of 2 months to allow patients to taper to dual therapy. • Additional agents may be added to existing dual therapy after a 2-week trial at the maximum tolerated dose of each agent. <p>Proposed Quantity Limits:</p> <table border="1" data-bbox="302 1482 1227 1593"> <thead> <tr> <th data-bbox="302 1482 659 1524">Drug</th> <th data-bbox="659 1482 878 1524">Strength</th> <th data-bbox="878 1482 1227 1524">Per Day Count</th> </tr> </thead> <tbody> <tr> <td data-bbox="302 1524 659 1560">Symbyax®</td> <td data-bbox="659 1524 878 1560">All Strengths</td> <td data-bbox="878 1524 1227 1560">1 per day</td> </tr> <tr> <td data-bbox="302 1560 659 1593">olanzapine/fluoxetine</td> <td data-bbox="659 1560 878 1593">All Strengths</td> <td data-bbox="878 1560 1227 1593">1 per day</td> </tr> </tbody> </table>	Drug	Strength	Per Day Count	Symbyax®	All Strengths	1 per day	olanzapine/fluoxetine	All Strengths	1 per day	<p>Passed</p> <p>10 For</p> <p>0 Against</p>
Drug	Strength	Per Day Count									
Symbyax®	All Strengths	1 per day									
olanzapine/fluoxetine	All Strengths	1 per day									

	Description of Recommendation	P & T Vote
19	<p><u>First Generation Anticonvulsants</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least all generic products should be preferred. 2. Agents not selected as preferred will be considered non preferred and require prior authorization. 3. Require therapeutic failure of one preferred agent prior to approval of a non-preferred agent. 4. For any agent not selected as preferred, DMS to allow continuation of therapy if there is a paid claim in the past 90 days. 5. For any new chemical entity in the First Generation Anticonvulsants class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed 10 For 0 Against</p>
20	<p><u>Second Generation Anticonvulsants</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least seven unique chemical entities should be preferred. 2. Agents not selected as preferred will be considered non preferred and require prior authorization. 3. Require therapeutic failure of one preferred agent prior to approval of a non-preferred agent. 4. For any agent not selected as preferred, DMS to allow continuation of therapy if there is a paid claim in the past 90 days. 5. For any new chemical entity in the Second Generation Anticonvulsants class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed 9 For 1 Against</p>
21	<p><u>Banzel™ Clinical Criteria</u> Banzel™ should be approved if:</p> <ul style="list-style-type: none"> • Diagnosis of Lennox-Gastaut syndrome; OR • Trial and failure of one other anticonvulsant. 	<p>Passed 10 For 0 Against</p>
22	<p><u>Lyrica® Clinical Criteria</u> Lyrica® should be approved if any ONE of the following is true:</p> <ul style="list-style-type: none"> • Diabetic Peripheral Neuropathy (DPN); OR • Neuropathic pain associated with spinal cord injury; OR • Postherpetic Neuralgia (PHN) AFTER adequate trial and failure of OR intolerance OR contraindication to at least one of these first-line agents <ul style="list-style-type: none"> ○ Tricyclic antidepressant (TCAs); or ○ Anticonvulsant: gabapentin; or ○ Topical: Lidocaine 5% patch. • Adjunct for partial onset seizure disorder; OR • Fibromyalgia. 	<p>Passed 10 For 0 Against</p>

	Description of Recommendation	P & T Vote
23	<p><u>Sabril® Clinical Criteria</u> Sabril® should be approved if:</p> <ul style="list-style-type: none"> • Diagnosis of infantile spasms; OR • Trial and failure of one other anticonvulsant. 	<p>Passed 10 For 0 Against</p>
24	<p><u>Anticonvulsants, Carbamazepine Derivatives</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least two unique chemical entities should be preferred. 2. Agents not selected as preferred will be considered non preferred and require prior authorization. 3. Require therapeutic failure of one preferred agent prior to approval of a non-preferred agent. 4. For any agent not selected as preferred, DMS to allow continuation of therapy if there is a paid claim in the past 90 days. 5. For any new chemical entity in the Anticonvulsants, Carbamazepine Derivatives class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed 10 For 0 Against</p>
25	<p><u>Stimulants and Related Agents</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent(s) based on economic evaluation; however, at least one short-acting, one intermediate-acting and one long-acting formulation of methylphenidate and dextroamphetamine as well as atomoxetine should be preferred. 2. Agents not selected as preferred will be considered non preferred and require prior approval. 3. Require appropriate ICD-9 on all prescriptions for agents within this class. 4. Continue to require prior authorization for modafinil and armodafinil to ensure utilization in FDA-approved indications only. 5. Place quantity limits on all agents based on the American Academy of Child and Adolescent Psychiatry and FDA-approved maximum recommended dose. 6. Allow only one agent at a time for an extended release product and one agent at a time for an immediate release product unless switching agents due to therapeutic failure. 7. Allow continuation of therapy for non preferred single-source branded products via a 90 day look back. 8. For any new chemical entity in the Stimulants and Related Agents class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed 10 For 0 Against</p>

	Description of Recommendation	P & T Vote																												
26	<p data-bbox="302 264 954 306"><u>Stimulants and Related Agents Clinical Criteria</u></p> <p data-bbox="302 338 886 380">Diagnosis to Approve via an ICD-9 Override:</p> <table border="1" data-bbox="302 411 1224 947"> <thead> <tr> <th data-bbox="302 411 802 453"><u>Diagnosis</u></th> <th data-bbox="802 411 1224 453"><u>ICD-9</u></th> </tr> </thead> <tbody> <tr> <td data-bbox="302 453 802 495">Attention Deficit/Hyperreactivity Disorder (ADHD)</td> <td data-bbox="802 453 1224 495">314.1</td> </tr> <tr> <td data-bbox="302 495 802 537"></td> <td data-bbox="802 495 1224 537">314.01</td> </tr> <tr> <td data-bbox="302 537 802 579"></td> <td data-bbox="802 537 1224 579">314.2</td> </tr> <tr> <td data-bbox="302 579 802 621"></td> <td data-bbox="802 579 1224 621">314.8</td> </tr> <tr> <td data-bbox="302 621 802 663"></td> <td data-bbox="802 621 1224 663">314.9</td> </tr> <tr> <td data-bbox="302 663 802 705">Attention Deficit Disorder (ADD)</td> <td data-bbox="802 663 1224 705">314.00</td> </tr> <tr> <td data-bbox="302 705 802 747">Narcolepsy</td> <td data-bbox="802 705 1224 747">347.00</td> </tr> <tr> <td data-bbox="302 747 802 789"></td> <td data-bbox="802 747 1224 789">347.01</td> </tr> <tr> <td data-bbox="302 789 802 831"></td> <td data-bbox="802 789 1224 831">347.11</td> </tr> <tr> <td data-bbox="302 831 802 873">Sleep apnea/hypoapnea syndrome</td> <td data-bbox="802 831 1224 873">780.57</td> </tr> <tr> <td data-bbox="302 873 802 915"></td> <td data-bbox="802 873 1224 915">780.51</td> </tr> <tr> <td data-bbox="302 915 802 947"></td> <td data-bbox="802 915 1224 947">780.53</td> </tr> <tr> <td data-bbox="302 947 802 989">Shift work sleep disorder</td> <td data-bbox="802 947 1224 989">307.45</td> </tr> </tbody> </table> <p data-bbox="302 978 1179 1094">**Agents may be approved for other diagnosis via the prior authorization process based on a review of the current literature by a clinical pharmacist.</p> <p data-bbox="302 1125 1195 1199">Daytrana™, Methylin® Solution, Methylin® Chewable Tabs, or Procentra™ will be approved if either of the following criteria is met:</p> <ul data-bbox="350 1209 1195 1493" style="list-style-type: none"> <li data-bbox="350 1209 1195 1272">• Trial and failure of two preferred products, one of which must be the same chemical as the requested medication; OR <li data-bbox="350 1283 1195 1493">• Inability to swallow/tolerate PO/whole tablets/capsules <ul data-bbox="448 1314 1195 1493" style="list-style-type: none"> <li data-bbox="448 1314 1195 1388">○ For Daytrana™, inability to swallow/tolerate PO medications; OR <li data-bbox="448 1398 1195 1493">○ For Methylin® Solution, Methylin® Chewable Tabs, or Procentra™, inability to swallow tablets or capsules whole. <p data-bbox="302 1503 643 1535"><u>Therapeutic Duplication</u></p> <p data-bbox="302 1545 1227 1900">Prior authorization will be required for more than one long-acting (Adderall XR®, Concerta®, Daytrana™, Dexedrine®, dextroamphetamine ER, Metadate CD®, Metadate ER®, Focalin XR™, Methylin ER®, methylphenidate ER, methylphenidate ER OROS, methylphenidate SR, mixed amphetamine salt ER, Ritalin LA®, Ritalin SR®, Strattera®, Vyvanse™), or more than one short-acting (Adderall®, Desoxyn®, dexmethylphenidate IR, dextroamphetamine IR, DextroStat®, Focalin™, methamphetamine, Methylin®, methylphenidate IR, mixed amphetamine salt IR, Procentra™, Ritalin®) stimulant at a time.</p>	<u>Diagnosis</u>	<u>ICD-9</u>	Attention Deficit/Hyperreactivity Disorder (ADHD)	314.1		314.01		314.2		314.8		314.9	Attention Deficit Disorder (ADD)	314.00	Narcolepsy	347.00		347.01		347.11	Sleep apnea/hypoapnea syndrome	780.57		780.51		780.53	Shift work sleep disorder	307.45	<p data-bbox="1252 264 1349 296">Passed</p> <p data-bbox="1252 306 1341 338">10 For</p> <p data-bbox="1252 348 1382 380">0 Against</p>
<u>Diagnosis</u>	<u>ICD-9</u>																													
Attention Deficit/Hyperreactivity Disorder (ADHD)	314.1																													
	314.01																													
	314.2																													
	314.8																													
	314.9																													
Attention Deficit Disorder (ADD)	314.00																													
Narcolepsy	347.00																													
	347.01																													
	347.11																													
Sleep apnea/hypoapnea syndrome	780.57																													
	780.51																													
	780.53																													
Shift work sleep disorder	307.45																													

	Description of Recommendation	P & T Vote														
27	<p><u>Strattera[®] Clinical Criteria</u> Strattera[®] (atomoxetine) will be approved if both of the following criteria are met:</p> <ul style="list-style-type: none"> • Diagnosis of: <table border="1" data-bbox="305 380 1227 646"> <thead> <tr> <th data-bbox="305 380 800 422">Diagnosis</th> <th data-bbox="805 380 1227 422">ICD-9</th> </tr> </thead> <tbody> <tr> <td data-bbox="305 422 800 495">Attention Deficit/Hyperreactivity Disorder (ADHD)</td> <td data-bbox="805 422 1227 453">314.1</td> </tr> <tr> <td></td> <td data-bbox="805 453 1227 485">314.01</td> </tr> <tr> <td></td> <td data-bbox="805 485 1227 516">314.2</td> </tr> <tr> <td></td> <td data-bbox="805 516 1227 548">314.8</td> </tr> <tr> <td></td> <td data-bbox="805 548 1227 579">314.9</td> </tr> <tr> <td data-bbox="305 600 800 646">Attention Deficit Disorder (ADD)</td> <td data-bbox="805 600 1227 646">314.00</td> </tr> </tbody> </table> <p>AND;</p> <ul style="list-style-type: none"> • Any one of the following criteria: <ul style="list-style-type: none"> ○ Trial and failure of one preferred stimulant and related agent in the past 90 days; OR ○ History of substance abuse or diversion on the part of the patient or caregiver; OR ○ History of stimulant-induced weight loss after trial of two stimulants; OR ○ History of tic disorder, including Tourette's; OR ○ Co-morbid mood or anxiety disorder. 	Diagnosis	ICD-9	Attention Deficit/Hyperreactivity Disorder (ADHD)	314.1		314.01		314.2		314.8		314.9	Attention Deficit Disorder (ADD)	314.00	Passed 10 For 0 Against
Diagnosis	ICD-9															
Attention Deficit/Hyperreactivity Disorder (ADHD)	314.1															
	314.01															
	314.2															
	314.8															
	314.9															
Attention Deficit Disorder (ADD)	314.00															
28	<p><u>Special Motion</u> The Committee would like to discuss the pros and cons of requiring placement of ICD-9s on prescriptions.</p>	Passed 9 For 0 Against 1 Abstention														
29	<p><u>Provigil[®]/Nuvigil[®] Clinical Criteria</u> Provigil[®] (modafinil) / Nuvigil[®] (armodafinil) will be approved if both of the following criteria are met:</p> <ul style="list-style-type: none"> • One of the following approvable diagnosis (via ICD-9 override): <table border="1" data-bbox="305 1346 1227 1612"> <tbody> <tr> <td data-bbox="305 1346 784 1388">Narcolepsy</td> <td data-bbox="789 1346 1227 1377">347.00</td> </tr> <tr> <td></td> <td data-bbox="789 1377 1227 1409">347.01</td> </tr> <tr> <td></td> <td data-bbox="789 1409 1227 1440">347.11</td> </tr> <tr> <td data-bbox="305 1461 784 1503">Sleep apnea/hypoapnea syndrome</td> <td data-bbox="789 1461 1227 1493">780.57</td> </tr> <tr> <td></td> <td data-bbox="789 1493 1227 1524">780.51</td> </tr> <tr> <td></td> <td data-bbox="789 1524 1227 1556">780.53</td> </tr> <tr> <td data-bbox="305 1577 784 1612">Shift work sleep disorder</td> <td data-bbox="789 1577 1227 1612">307.45</td> </tr> </tbody> </table> <ul style="list-style-type: none"> • For Nuvigil[®] (armodafinil) ONLY, trial and failure of Provigil[®] (modafinil) 	Narcolepsy	347.00		347.01		347.11	Sleep apnea/hypoapnea syndrome	780.57		780.51		780.53	Shift work sleep disorder	307.45	Passed 10 For 0 Against
Narcolepsy	347.00															
	347.01															
	347.11															
Sleep apnea/hypoapnea syndrome	780.57															
	780.51															
	780.53															
Shift work sleep disorder	307.45															

	Description of Recommendation	P & T Vote
30	<p><u>SSRIs</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent(s) based upon economic evaluation; however, at least three unique chemical entities should be preferred. 2. Agents not selected as preferred will be considered non-preferred and will require Prior Authorization. 3. Any new chemical entity in the SSRI class should require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed 10 For 0 Against</p>
31	<p><u>SNRIs</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent(s) based upon economic evaluation; however, at least one long acting SNRI should be preferred. 2. Agents not selected as preferred will be considered non-preferred and will require Prior Authorization. 3. Clinical criteria should be placed on milnacipran to ensure it is being used for its FDA-approved indication only. 4. Any new chemical entity in the SNRI class should require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed 10 For 0 Against</p>
32	<p><u>Cymbalta[®] Clinical Criteria</u></p> <p>Cymbalta[®] should be authorized for the following diagnoses:</p> <ul style="list-style-type: none"> • Depression/Major Depressive Disorder/Generalized Anxiety Disorder/Social Anxiety Disorder/Panic Disorder: Approval after trial and failure or intolerance or contraindication to one preferred SNRI. • Diabetic peripheral neuropathic pain • Fibromyalgia • Chronic musculoskeletal pain: Approval after trial and failure of or intolerance or contraindication to one NSAID. 	<p>Passed 10 For 0 Against</p>